Peptide composition
AssigneeApitope Technology (Bristol) Limited
InventorsDavid Wraith, Heather Barbara Streeter
Life of this patent
Estimating the term…
Loading patent…
AssigneeApitope Technology (Bristol) Limited
InventorsDavid Wraith, Heather Barbara Streeter
Estimating the term…
There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.
1-15. (canceled)
A method of inducing T cell tolerance to myelin basic protein in a subject in need of same which comprises the step of administering a peptide MBP 30-44 (SEQ ID NO:
(canceled)
A method according to claim 16, 18 or 20, wherein the peptide is administered intranasally.
Dependencies are inferred from the claim text.